IP Library Granted Patent US 9,775,884
Granted Patent B2
US 9,775,884 · App. 12/532,547 · Granted Oct 3, 2017

Solid fibrinogen preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,775,884
App. No.
12/532,547
Granted
Oct 3, 2017
Kind
B2
Abstract

A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.

Claims (32)

1. A solid fibrinogen composition comprising

fibrinogen, albumin, a non-ionic surfactant and a combination of amino acid or amino acid salts selected from the group consisting of:

isoleucine, glycine, arginine, and glutamic acid, or salts thereof (IGRE);

glycine, arginine, and glutamic acid, or salts thereof (GRE);

isoleucine, glycine, and arginine, or salts thereof (IGR);

leucine, glycine, arginine, and glutamic acid, or salts thereof (LGRE);

isoleucine, alanine, arginine, and glutamic acid, or salts thereof (IARE);

isoleucine, serine, arginine, and glutamic acid, or salts thereof (ISRE);

isoleucine, threonine, arginine, and glutamic acid, or salts thereof (ITRE);

isoleucine, glutamine, arginine, and glutamic acid, or salts thereof (IQRE); and

isoleucine, glycine, lysine and glutamic acid, or salts thereof (IGKE).

2. The solid fibrinogen composition of claim 1 , wherein the surfactant is tyloxapol or polysorbate 80 .

3. The solid fibrinogen composition of claim 1 , further comprising at least one of a monofilament, cotton, paper, cellulose, cellulose derivative, nonwoven fabric, textile, knit, sponge, film or other supporting material.

4. The solid composition of claim 1 , further comprising at least one of collagen, gelatin, polyglycolic acid, polylactic acid, glycolic acid-lactic acid copolymer, polyglutamic acid, or amylose.

5. The solid fibrinogen composition of claim 1 in a lyophilized form and suitable for medical use.

6. A liquid composition produced by contacting water with the solid fibrinogen composition of claim 1 .

7. The liquid composition of claim 6 that rehydrates faster or that has a shorter defoaming time than an otherwise identical composition produced by contacting water with a solid fibrinogen composition that does not contain at least one of albumin, a non-ionic surfactant, or one of the amino acids or amino acid salts in the combination of amino acids or amino acid salts.

8. A solid fibrinogen composition comprising fibrinogen, albumin, a non-ionic surfactant, and a combination of amino acids or amino acid salts selected from the group consisting of:

glycine or a glycine salt, arginine or a salt of arginine, glutamic acid or a salt of glutamic acid (GRE); and

isoleucine or an isoleucine salt, glycine or a glycine salt, arginine or a salt of arginine, (IGR).

9. The solid fibrinogen composition of claim 8 , wherein the surfactant is tyloxapol or polysorbate 80 .

10. The solid fibrinogen composition of claim 8 , further comprising at least one of a monofilament, cotton, paper, cellulose, cellulose derivative, nonwoven fabric, textile, knit, sponge, film or other supporting material.

11. The solid fibrinogen composition of claim 8 , further comprising at least one of collagen, gelatin, polyglycolic acid, polylactic acid, glycolic acid-lactic acid copolymer, polyglutamic acid, or amylose.

12. The solid fibrinogen composition of claim 8 in a lyophilized form and suitable for medical use.

13. A liquid composition produced by contacting water with the solid fibrinogen composition of claim 8 .

14. The liquid composition of claim 13 that rehydrates faster or that has a shorter defoaming time than an otherwise identical composition produced by contacting water with a solid fibrinogen composition that does not contain at least one of albumin, a non-ionic surfactant, or one of the amino acids or amino acid salts in the combination of amino acids or amino acid salts.

15. A solid fibrinogen composition comprising fibrinogen, albumin, a non-ionic surfactant, and isoleucine or an isoleucine salt, glycine or a glycine salt, arginine or a salt of arginine, glutamic acid or a salt of glutamic acid (IGRE).

16. The solid fibrinogen composition of claim 15 , wherein the surfactant is tyloxapol or polysorbate 80 .

17. The solid fibrinogen composition of claim 15 , further comprising at least one of a monofilament, cotton, paper, cellulose, cellulose derivative, nonwoven fabric, textile, knit, sponge, film or other supporting material.

18. The solid fibrinogen composition of claim 15 , further comprising at least one of collagen, gelatin, polyglycolic acid, polylactic acid, glycolic acid-lactic acid copolymer, polyglutamic acid, or amylose.

19. A liquid composition produced by contacting water with the solid fibrinogen composition of claim 15 .

20. The liquid composition of claim 19 that rehydrates faster or that has a shorter defoaming time than an otherwise identical composition produced by contacting water with a solid fibrinogen composition that does not contain at least one of albumin, a non-ionic surfactant, isoleucine or an isoleucine salt, glycine or a glycine salt, arginine or a salt of arginine, or glutamic acid or a salt of glutamic acid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2009
From: MIYAGAWA, SHINICHI; ARAKI, TATSUYA; HAMURO, TSUTOMU; OKUDA, MIKA; KAETSU, HIROSHI
To: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 023503/0309 →